KEGG   DRUG: Lebrikizumab
Entry
D09633                      Drug                                   
Name
Lebrikizumab (USAN/INN);
Lebrikizumab (genetical recombination) (JAN)
Formula
C6434H9972N1700O2034S50
Exact mass
145195.5169
Mol weight
145285.4411
Sequence
(Heavy chain)
QVTLRESGPA LVKPTQTLTL TCTVSGFSLS AYSVNWIRQP PGKALEWLAM IWGDGKIVYN
SALKSRLTIS KDTSKNQVVL TMTNMDPVDT ATYYCAGDGY YPYAMDNWGQ GSLVTVSSAS
TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP PSQEEMTKNQ
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSRLTV DKSRWQEGNV
FSCSVMHEAL HNHYTQKSLS LSLGK
(Light chain)
DIVMTQSPDS LSVSLGERAT INCRASKSVD SYGNSFMHWY QQKPGQPPKL LIYLASNLES
GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQNNEDPR TFGGGTKVEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: H22-H95, H145-H201, H259-H319, H365-H423, H224-H'224, H227-H'227, L23-L92, L138-L198, H132-L218)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Efficacy
Antiasthmatic, Anti-IL-13 antibody
Comment
Monoclonal antibody
Target
IL13 [HSA:3596] [KO:K05435]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
hsa05310  Asthma
Brite
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D09633  Lebrikizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL13
     D09633  Lebrikizumab (USAN/INN)
Other DBs
CAS: 953400-68-5
PubChem: 124490373
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system